NYSE:NUVB Nuvation Bio Q3 2026 Earnings Report $4.96 -0.18 (-3.40%) Closing price 03:59 PM EasternExtended Trading$4.94 -0.02 (-0.46%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nuvation Bio EPS ResultsActual EPSN/AConsensus EPS -$0.12Beat/MissN/AOne Year Ago EPSN/ANuvation Bio Revenue ResultsActual RevenueN/AExpected Revenue$35.61 millionBeat/MissN/AYoY Revenue GrowthN/ANuvation Bio Announcement DetailsQuarterQ3 2026Date11/2/2026TimeBefore Market OpensConference Call DateMonday, November 2, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Nuvation Bio Earnings HeadlinesContrasting Nuvation Bio (NYSE:NUVB) & Janux Therapeutics (NASDAQ:JANX)October 3 at 5:15 AM | americanbankingnews.comCitigroup Initiates Coverage on Nuvation Bio (NYSE:NUVB)October 2 at 1:48 AM | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 5 at 1:00 AM | Investors Alley (Ad)Citigroup initiates coverage of Nuvation Bio with buyOctober 1, 2026 | msn.comCitigroup Initiates Nuvation Bio at Buy With $12 Price TargetSeptember 30, 2026 | marketscreener.comMNuvation Bio Inc. (NYSE:NUVB) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesSeptember 30, 2026 | americanbankingnews.comSee More Nuvation Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email. Email Address About Nuvation BioNuvation Bio (NYSE:NUVB), Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses small-molecule drug discovery and development approaches to pursue therapies intended to address difficult-to-treat tumors and areas of significant unmet medical need. Nuvation Bio’s pipeline has included NUV-868, an oral investigational inhibitor of DYRK1A being studied in solid tumors, and NUV-1511, an investigational oncology drug designed to interfere with cancer-cell DNA damage response mechanisms. The company has also expanded its development capabilities through the acquisition of AnHeart Therapeutics, adding radiopharmaceutical research and development programs to its broader oncology portfolio. Nuvation Bio was founded by David Hung, M.D., who serves as the company’s founder, president and chief executive officer. The company became a publicly traded business in 2021 and is headquartered in the United States, where it conducts its research and development activities in collaboration with clinical and scientific partners.View Nuvation Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
